A New Prostate Cancers Treatment Strategy

A New Prostate Cancers Treatment Strategy.
Conventional prudence has it that pongy levels of testosterone help prostate cancers grow. However, a new, small swatting suggests that a treatment strategy called bipolar androgen therapy - where patients alternative between low and high levels of testosterone - might make prostate tumors more responsive to labarum hormonal therapy. As the researchers explained, the primary treatment for advanced prostate cancer is hormonal therapy, which lowers levels of testosterone to stop the tumor from growing. But there's a problem: Prostate cancer cells inevitably worst the therapy by increasing their ability to suck up any unused testosterone in the body.

The new strategy forces the tumor to respond again to higher testosterone levels, portion to reverse its resistance to standard therapy, the researchers say. If confirmed in several ceaseless larger trials, "this could lead to a new treatment approach" for prostate cancers that have grown unaffected to hormonal therapy, said lead researcher Dr Michael Schweizer, an aid professor of oncology at the University of Washington School of Medicine in Seattle.

So "It needs to be stressed that bipolar androgen treatment is not ready for adoption into routine clinical practice, since these studies have not been completed. The backfire was published Jan 7, 2015 in the journal Science Translational Medicine. For the study, 16 men with hormone therapy-resistant prostate cancer received bipolar androgen therapy. Of these patients, seven had their cancer go into remission. In four men, tumors shrank, and in one man, tumors disappeared completely, the researchers report.

Complex Diagnostic Of Prostate Cancer

Complex Diagnostic Of Prostate Cancer.
Prostate biopsies that join MRI technology with ultrasound appear to give men better facts regarding the seriousness of their cancer, a new study suggests. The further technology - which uses MRI scans to help doctors biopsy very specified portions of the prostate - diagnosed 30 percent more high-risk cancers than paradigm prostate biopsies in men suspected of prostate cancer, researchers reported. These MRI-targeted biopsies also were better at weeding out low-risk prostate cancers that would not direct to a man's death, diagnosing 17 percent fewer low-grade tumors than classic biopsy, said senior author Dr Peter Pinto.

He is run of the prostate cancer section at the US National Cancer Institute's Center for Cancer Research in Bethesda, MD. These results evince that MRI-targeted biopsy is "a better temperament of biopsy that finds the aggressive tumors that need to be treated but also not finding those undersized microscopic low-grade tumors that are not clinically important but lead to overtreatment". Findings from the study are published in the Jan 27, 2015 Journal of the American Medical Association.

Doctors performing a measure biopsy use ultrasound to influence needles into a man's prostate gland, generally taking 12 core samples from preplanned sections. The problem is, this type of biopsy can be inaccurate, said analyse lead author Dr Mohummad Minhaj Siddiqui, an assistant professor of surgery at the University of Maryland School of Medicine and headman of urologic robotic surgery at the University of Maryland Marlene and Stewart Greenebaum Cancer Center in Baltimore.

And "Occasionally you may be nostalgic for the cancer or you may glance the cancer, just get an lip of it, and then you don't know the full extent of the problem". In a targeted biopsy, MRIs of the suspected cancer are fused with real-time ultrasound images, creating a map of the prostate that enables doctors to pinpoint and investigation unbelieving areas. Prostate cancer testing has become pretty controversial in recent years, with medical experts debating whether too many men are being diagnosed and treated for tumors that would not have led to their deaths.

Removal of the prostate gland can cause unworthy side effects, including impotence and incontinence, according to the US National Cancer Institute. But, even if a tumor isn't life-threatening, it can be psychologically laborious not to manage the tumor. To test the effectiveness of MRI-targeted biopsy, researchers examined just over 1000 men who were suspected of prostate cancer because of an freakish blood screening or rectal exam.

New Blood Test Can Detect Prostate Cancer More Accurately And Earlier

New Blood Test Can Detect Prostate Cancer More Accurately And Earlier.
A untrodden blood probe to spot a cluster of specific proteins may evidence the presence of prostate cancer more accurately and earlier than is now possible, new research suggests. The test, which has thus far only been assessed in a lead study, is 90 percent accurate and returned fewer false-positive results than the prostate fixed antigen (PSA) test, which is the current clinical standard, the researchers added. Representatives of the British public limited company that developed the test, Oxford Gene Technology in Oxford, presented the findings Tuesday at the International Conference on Molecular Diagnostics in Cancer Therapeutic Development in Denver, hosted by the American Association for Cancer Research.

The examine looks for auto-antibodies for cancer, alike to the auto-antibodies associated with autoimmune diseases such as variety 1 diabetes, rheumatoid arthritis and lupus. "These are antibodies against our own proteins," explained John Anson, Oxford's transgression president of biomarker discovery. "We're tiring to look for antibodies generated in the beginning stages of cancer. This is an exquisitely sensitive mechanism that we're exploring with this technology".

Such a study generates some excitement not only because it could theoretically detect tumors earlier, when they are more treatable, but auto-antibodies can be "easily detected in blood serum. It's not an invasive technique. It's a unassuming blood test". The researchers came up with groups of up to 15 biomarkers that were exhibit in prostate cancer samples and not present in men without prostate cancer. The exam also was able to differentiate actual prostate cancer from a more benign condition.

Because a apparent is currently pending, Anson would not list the proteins included in the test. "We are prosperous on to a much more exhaustive follow-on study. At the moment, we are taking over 1,800 samples, which includes 1,200 controls with a well range of 'interfering diseases' that men of 50-plus are prone to and are running a very large analytical validation study".

PSA Kinetics Is Not A Sufficient Indication For The Treatment Of Prostate Cancer

PSA Kinetics Is Not A Sufficient Indication For The Treatment Of Prostate Cancer.
A approach that urologists had hoped would prepare it credible to distinguish men with prostate cancer who need treatment from those who would only need watchful waiting didn't function well, researchers report. The technique, called PSA kinetics, measures changes in the deserve at which the prostate gland produces a protein called prostate-specific antigen. A significant enhancement in PSA kinetics, measured by the time during which PSA production doubles or increases at a fast rate, is supposed to indicate the need for treatment, by radiation therapy or surgery.

PSA kinetics has covet been used to measure the effectiveness of treatment. A number of cancer centers have started to use it as a reasonable method of distinguishing aggressive cancers that require treatment from those that are so slow-growing that they can safely be left alone.

Recent studies indicating that many men with slow-growing prostate cancers be subjected to unnecessary treatment have given stress to the search for such a tool, especially considering that side effects of treatment can include incontinence and impotence. But the ponder indicates that "PSA kinetics doesn't seem to be enough to show you who you should follow and who you should treat," said Dr Ashley E Ross, a urology dwelling at the Johns Hopkins University Brady Urological Institute, and move author of a report on the technique published online May 3 in the Journal of Clinical Oncology.

The promulgate describes the results of PSA kinetics measurements of 290 men with low-grade prostate cancer - the amicable that often doesn't require treatment - for an average of 2,9 years. The results of PSA tests were compared with biopsies - pack samples - that regular the progression of the cancers.

The trial is part of a study, under supervision of Dr H Ballentine Carter, kingpin of the division of adult urology at the Brady Urological Institute, that began in 1994. Men in the whirl had PSA tests every six months and biopsies every year.

Effect Of Anesthesia In Surgery Of Prostate Cancer

Effect Of Anesthesia In Surgery Of Prostate Cancer.
For men having prostate cancer surgery, the paradigm of anesthesia doctors use might commission a idiosyncrasy in the odds of the cancer returning, a new study suggests. Researchers found that of nearly 3300 men who underwent prostate cancer surgery, those who were given both widespread and regional anesthesia had a lower risk of seeing their cancer develop than men who received only general anesthesia. Over a period of 15 years, about 5 percent of men given only extended anesthesia had their cancer recur in their bones or other sites, the researchers said.

That compared with 3 percent of men who also received regional anesthesia, which typically meant a spinal injection of the anodyne morphine, increased by a numbing agent. None of that, however, proves that anesthesia choices straight affect a prostate cancer patient's prognosis. "We can't conclude from this that it's cause-and-effect," said elder researcher Dr Juraj Sprung, an anesthesiologist at the Mayo Clinic in Rochester, Minn.

But one theory is that spinal painkillers - get a bang the opioid morphine - can form a difference because they curb patients' need for opioid drugs after surgery. Those post-surgery opioids, which move the whole body, may decrease the immune system's effectiveness. That's potentially worthy because during prostate cancer surgery, some cancer cells usually emanate into the bloodstream - and a fully functioning immune response might be needed to kill them off. "If you from opioids after surgery, you may be increasing your ability to fight off these cancer cells.

The study, reported online Dec 17, 2013 in the British Journal of Anaesthesia, is not the primary to see a connection between regional anesthesia and a lower risk of cancer recurrence or progression. Some past studies have seen a almost identical pattern in patients having surgery for breast, ovarian or colon cancer. But those studies, liking for the current one, point only to a correlation, not a cause-and-effect link. Dr David Samadi, primary of urology at Lenox Hill Hospital in New York City, agreed.

Statins May Reduce The Risk Of Prostate Cancer

Statins May Reduce The Risk Of Prostate Cancer.
Cholesterol-lowering statins significantly cut down prostate tumor inflammation, which may worker lower the risk of disease progression, creative study findings suggest. Duke University Medical Center researchers found that the use of statins before prostate cancer surgery was associated with a 69 percent reduced good chance of inflammation arranged prostate tumors.

For the study, the researchers examined tissue samples of prostate tumors from 236 men undergoing prostate cancer surgery. The patients included 37 who took statins during the year latest to their surgery.

Overall, 82 percent of the men had treacherous cells in their prostate tumors and about one-third had prominent tumor inflammation. After they accounted for factors such as age, tear and body-mass index (a measurement that is based on weight and height), the Duke team concluded that statin use was associated with reduced swelling within tumors.

Smoking And Weight Gain Increases The Death Rate From Prostate Cancer

Smoking And Weight Gain Increases The Death Rate From Prostate Cancer.
Men treated for prostate cancer who smoke or put on superfluity pounds arouse their difference of disease recurrence and of dying from the illness, two new studies show. The findings were presented Tuesday at the American Association for Cancer Research's annual union in Washington, DC.

In the beforehand report, a team led by Dr Jing Ma, an associate professor of nostrum at Brigham and Women's Hospital in Boston, found that obesity and smoking may not be risk factors for developing prostate cancer, but they do lengthen the odds that a man who has the illness will die from it. Being ample and smoking "predispose men to a significantly high risk of cancer-specific and all-cause mortality," Ma said during a Tuesday forenoon news conference.

"Compared to lean non-smokers, obese smokers had the highest imperil of prostate cancer mortality". For the study, Ma's team collected data on more than 2700 men with prostate cancer who took leave in the Physicians Health Study. Over 27 years of follow-up, 882 of the men died, 11 percent from the cancer.

The researchers found that both worth move further and smoking boosted the risk for dying from the cancer. In fact, every five-point better in body mass index (BMI) increased the risk for dying from prostate cancer by 52 percent. BMI is a time of height versus weight, with the threshold of overweight set at a BMI of 25 and the edge for obesity set at a BMI of 30.

In addition, men who smoked increased their risk for dying from the cancer by 55 percent, compared with men who never smoked, the studio found. "These data underscore the penury for implementing effective preventive strategies for weight control and reducing tobacco use in both nourishing men as well as prostate cancer patients".

In a second report, a team led by Corinne E Joshu, a postdoctoral auxiliary in the department of epidemiology at Johns Hopkins Bloomberg School of Public Health, found that men who gained charge after having their prostate removed were almost twice as likely to aid their cancer return as were men who maintained their weight. "Weight gain may increase the risk of prostate cancer recurrence after prostatectomy," Joshu said during the AACR dirt conference.

"Obesity, especially among placid men, may also contribute to the risk of prostate cancer recurrence". For the study, Joshu's pair collected data on more than 1300 men with localized prostate cancer who underwent prostatectomy between 1993 and 2006. In addition, the men completed a inspection on diet, lifestyle and other factors such as weight, pinnacle and physical activity five years before surgery and again one year after the procedure.

An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects

An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects.
The newly approved medical prostate cancer vaccine, Provenge, is innocuous and has few position effects, a new study finds. In April, the US Food and Drug Administration approved the vaccine for use in men with advanced prostate cancer who had failed hormone therapy. "Provenge was approved based on both safeness and clinical data," said head researcher Dr Simon J Hall, chairman of urology at Mount Sinai Medical Center in New York City.

This sanctuary data shows that there are very limited side effects. The gain of the vaccine for patients with metastatic hormone-resistant prostate cancer is that it has fewer side slang shit than chemotherapy, which is the only other treatment option for these patients. In addition, Provenge has improved survival over chemotherapy.

The ordinary survival time for men given Provenge is 4,5 months, although some patients saw their lives extended by two to three years. "This is a newly close by treatment, with very limited surface effects, compared to anything else that a man would be considering in this state". Hall was to present the results on Monday at the American Urological Association annual assignation in San Francisco.

Data from four phase 3 trials, which included 904 men randomized to either Provenge or placebo, showed the vaccine extended survival, improved supremacy of freshness and had only mild side effects. In fact, more than 83 percent of the men who received Provenge were able to do appear as activities without any restrictions, the researchers noted.

Slowly Progressive Prostate Cancer Need To Be Watched Instead Of Treatment

Slowly Progressive Prostate Cancer Need To Be Watched Instead Of Treatment.
For patients with prostate cancer that has a low-lying jeopardize of progression, effectual surveillance, also known as "watchful waiting," may be a suitable treatment option, according to a large-scale study from Sweden. The issuance of how (or whether) to treat localized prostate cancer is controversial because, especially for older men, the tumor may not press on far enough to cause real trouble during their remaining expected lifespan. In those cases, deferring care until there are signs of disease progression may be the better option.

The researchers looked at almost 6900 patients from the National Prostate Cancer Registry Sweden, length of existence 70 or younger, who had localized prostate cancer and a stubby or intermediate risk that the cancer would progress. From 1997 through December 2002, over 2000 patients were assigned to on the move surveillance, close to 3400 underwent exhaustive prostatectomy (removal of the prostate and some surrounding tissue), and more than 1400 received radiation therapy.

Smoking And Excess Weight Can Lead To A Cancer

Smoking And Excess Weight Can Lead To A Cancer.
Men with prostate cancer may hike their survival chances if they refund animal fats and carbohydrates in their chamber with healthy fats such as olive oils, nuts and avocados, new research suggests June 2013. Men who substituted 10 percent of their diurnal calories from animal fats and carbs with such hale fats as olive oil, canola oil, nuts, seeds and avocados were 29 percent less like as not to die from spreading prostate cancer and 26 percent less probably to die from any other disease when compared to men who did not make this healthy swap, the study found. And a wee bit seems to go a long way.

Specifically, adding just one daily tablespoon of an oil-based salad dressing resulted in a 29 percent mark down risk of dying from prostate cancer and a 13 percent put down risk of dying from any other cause, the study contended. In the study, nearly 4600 men who had localized or non-spreading prostate cancer were followed for more than eight years, on average. During the study, 1064 men died.

Of these, 31 percent died from humanity disease, somewhat more than 21 percent died as a outcome of prostate cancer and slightly less than 21 percent died as a follow-up of another type of cancer. The findings appeared online June 10 in JAMA Internal Medicine. The read can't say for sure that including healthy fats in the slim was responsible for the survival edge seen among men.

Radiation Treatment Of Prostate Cancer

Radiation Treatment Of Prostate Cancer.
Smoking doubles the chances that a prostate cancer constant will go out with his disease spread and that he will eventually die from his illness, a new investigation finds. "Basically we found that people who smoke had a higher risk of their tumor coming back, of it spreading and, ultimately, even moribund of prostate cancer," said study co-author Dr Michael Zelefsky. He is depravity chair of clinical research in the department of radiation oncology at Memorial Sloan Kettering Cancer Center in New York City. "But interestingly, this applied only to 'current smokers' who were smoking around the occasion they received outer beam therapy," Zelefsky added, referring to the ordinary form of radiation treatment for prostate cancer.

So "Former smokers did not have the increased hazard for disease spread and recurrence that current smokers did. "However, we also looked at how smoking seized treatment side effects," from the radiation treatment, which can include rectal bleeding and/or regular and urgent urination. "And we saw that both patients who smoked and former smokers seemed to have a higher danger of urinary-related side effects after therapy".

Zelefsky and his colleagues reported the findings online Jan 27, 2015 in the list BJU International. The research team piercing out that 19 percent of American adults smoke. To explore the impact of smoking narration on prostate cancer treatment and progression, the study authors focused on nearly 2400 patients who underwent therapy for prostate cancer between 1988 and 2005. Nearly 50 percent were identified as "former smokers," even if they had only kicked their vestments shortly before beginning cancer treatment.

Disease progression, relapse, symptoms and deaths were all tracked for an mediocre of eight years, as were all reactions to the radiation treatment. The researchers resolved that the likelihood of surviving prostate cancer for a decade without experiencing any disease recurrence was about 66 percent centre of patients who had never smoked. By comparison, that figure fell to 52 percent amidst patients who were current smokers.

Smoking And Excess Weight Can Lead To A Cancer

Smoking And Excess Weight Can Lead To A Cancer.
Men with prostate cancer may rise their survival chances if they restore animal fats and carbohydrates in their nutriment with healthy fats such as olive oils, nuts and avocados, new research suggests June 2013. Men who substituted 10 percent of their routine calories from animal fats and carbs with such beneficial fats as olive oil, canola oil, nuts, seeds and avocados were 29 percent less indubitably to die from spreading prostate cancer and 26 percent less meet to die from any other disease when compared to men who did not make this healthy swap, the study found. And a miniature bit seems to go a long way.

Specifically, adding just one daily tablespoon of an oil-based salad dressing resulted in a 29 percent demean risk of dying from prostate cancer and a 13 percent earlier risk of dying from any other cause, the study contended. In the study, nearly 4600 men who had localized or non-spreading prostate cancer were followed for more than eight years, on average. During the study, 1064 men died.

Of these, 31 percent died from marrow disease, slight more than 21 percent died as a follow-up of prostate cancer and slightly less than 21 percent died as a upshot of another type of cancer. The findings appeared online June 10 in JAMA Internal Medicine. The swat can't say for sure that including healthy fats in the council was responsible for the survival edge seen among men.

New Ways Of Treating Prostate Cancer And Ovarian Cancer

New Ways Of Treating Prostate Cancer And Ovarian Cancer.
New investigate supports creative ways to treat ovarian and prostate cancer, while producing a mortification for those with a certain form of colon cancer. Both the ovarian and prostate cancer trials could interchange clinical practice, with more women taking the drug bevacizumab (Avastin) to combat the affliction in its advanced stages and more men getting radiation therapy for locally advanced prostate cancer, according to researchers who presented the findings Sunday at the American Society of Clinical Oncology (ASCO) annual meet in Chicago. A third trial, looking at the effectiveness of cetuximab (Erbitux) in treating undoubted colon cancer patients, found the antidepressant made little difference to their survival.

The first swot found that adding Avastin to standard chemotherapy (carboplatin and paclitaxel) and continuing with "maintenance" Avastin after chemo as a matter of fact slowed the time-to-disease recurrence in women with advanced ovarian cancer. Avastin is an anti-angiogenic drug, gist it interferes with a tumor's blood supply. "This is the first molecular-targeted and opening anti-angiogenesis therapy to demonstrate benefit in this population and, combined with chemotherapy followed by Avastin maintenance, should be considered as one law option for women with this disease," said lead researcher Dr Robert A Burger, governor of the Women's Cancer Center at Fox Chase Cancer Center in Philadelphia.

So "This is a unusual potential treatment paradigm for stage 3 and 4 ovarian cancer," added Dr Jennifer Obel, an attending medical doctor at Northshore University Health System and arbiter of a Sunday news conference at which these results were presented. The phase 3 think over involved almost 1,900 women with stage 3 and stage 4 ovarian cancer. Those who received canon chemotherapy plus Avastin, and then maintenance Avastin, for up to 10 months lived just over 14 months without their complaint progressing compared with about 10 months for those receiving example chemotherapy alone.

Those who received chemo plus Avastin but no maintenance drug lived without a recurrence for 11,3 months, a diversity not considered statistically significant. "I'm cautiously optimistic about this data. It utterly shows that those who had maintenance Avastin had improved profession-free survival," said Dr Robert Morgan, co-director of the gynecologic oncology program at City of Hope Cancer Center in Duarte, Calif. "I ruminate we have to heels for longer term outcomes before we make particular conclusions. It's too early for overall survival benefit data".

However, he pointed out, a four-month conversion for progression-free survival is "substantial". Doctors are already using Avastin off-label widely to treat ovarian cancer, he said, although it is not yet approved for this use. It has been shown to be more effective in this cancer than in many cancers for which it is approved, Morgan noted.

In Men With Prostate Cancer Observed Decrease In Penis Size

In Men With Prostate Cancer Observed Decrease In Penis Size.
A flat million of men with prostate cancer complain that their penis appears to be shorter following treatment, doctors report. According to researchers from the Dana-Farber Cancer Institute and Brigham and Women's Cancer Center, Boston, these patients said that this unexpected ancillary implication interfered with their insinuate relationships and made them regret the type of treatment they had chosen. "Prostate cancer is one of the few cancers where patients have a exquisite of therapies, and because of the range of possible side effects, it can be a tough choice," mull over leader Dr Paul Nguyen, a radiation oncologist, said in a Dana-Farber news release.

So "This workroom says that when penile shortening does occur, it really does affect patients and their nobility of life. It's something we should be discussing up front so that it will help reduce treatment regrets". The cause effect was most common among men who had prostatectomies, which is the surgical removal of the prostate, and those who had hormone-based remedy coupled with radiation. Nguyen added that most patients are able to cope with just about any side effect if they remember about it in advance.

The study involved 948 men with recurrent prostate cancer. The men were enrolled in a registry that collects message on patients whose prostate cancer shows signs of coming back after their primary treatment. Most of the men were between the ages of 60 and 80. Of the men snarled in the study, 54 percent had their prostate surgically removed, 24 percent received dispersal combined with hormone-blocking treatment and 22 percent chose to undergo only radiation.

Weather Conditions May Affect Prostate Cancer Patients

Weather Conditions May Affect Prostate Cancer Patients.
A unique scrutiny links dry, cold weather to higher rates of prostate cancer. While the findings don't clinch a direct link, researchers suspect that weather may affect dirtying and, in turn, boost prostate cancer rates. "We found that colder weather, and down rainfall, were strongly correlated with prostate cancer," researcher Sophie St-Hilaire, of Idaho State University, said in a statement release.

So "Although we can't say exactly why this correlation exists, the trends are conforming with what we would expect given the effects of climate on the deposition, absorption, and degradation of persistent primary pollutants including pesticides". St-Hilaire and colleagues studied prostate cancer rates in counties in the United States and looked for links to restricted weather patterns.

They found a link, and suggest it may exist because heatless weather slows the degradation of pollutants. Prostate cancer will strike about one in six men, according to training information in the study. Reports suggest it's more common in the northern hemisphere.